You are here: Home » Current Affairs » Coronavirus » News
Business Standard

Bharat Biotech follows SII, reduces Covaxin price to Rs 400 for states

Earlier, the Bharat Biotech vaccine was priced at Rs 600 a dose

Coronavirus | Coronavirus Vaccine | Bharat Biotech

Sohini Das  |  Mumbai 

Covaxin, bharat biotech, covid, coronavirus, vaccine, drugs, medicine, pharma

on Thursday reduced the price of Covaxin, an indigenously developed Covid-19 vaccine, by 33 per cent for state governments to Rs 400 a dose. Earlier, it was priced at Rs 600 a dose. The prices for the international market ($15-20 a dose) and private hospitals (Rs 1,200 a dose) remain the same as previously announced.

The move came a day after Serum Institute of India cut the price of its Covishield vaccine to Rs 300 from Rs 400 a dose for states. On Monday, the Centre had asked the two vaccine makers to reduce their prices, following objections by states over the differential pricing.

said that “recognising the enormous challenges to the public healthcare system”, it had decided to make Covaxin available for state governments for Rs 400 a dose.

he Hyderabad-based firm reiterated that the approach to pricing was determined by internally funded product development, several operationally intensive BSL -3 manufacturing facilities.

The Centre has sanctioned Rs 1,500 crore as suppliers’ credit for to buy future doses of vaccines. It has also received a grant of over Rs 130 crore from the Centre to augment its production capacities to 100 million doses per month by September. At present, the company is able to produce 10 million doses a month and a ramp-up plan is in the works.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Thu, April 29 2021. 23:17 IST